You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 41 No. 6, June 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cerebellar Norepinephrine in Patients With Parkinson's Disease and Control Subjects

Stephen J. Kish, PhD; Kathleen S. Shannak; Ali H. Rajput, MD; Joseph J. Gilbert, MD; Oleh Hornykiewicz, MD

Arch Neurol. 1984;41(6):612-614.


Abstract

• Norepinephrine was measured in postmortem cerebellar cortex of 22 non-neurological control subjects and nine patients with Parkinson's disease, using the high-performance liquid chromatography method with amperometric detection. In all control subjects, substantial amounts of norepinephrine were found in cerebellar cortex. There was a moderate negative correlation between age of control subjects and cerebellar norepinephrine concentration. In the patients with Parkinson's disease, the cerebellar cortical norepinephrine levels were significantly below normal. This is in accord with previously reported reduced norepinephrine levels in locus ceruleus and other regions of the parkinsonian brain. Although the main symptoms of Parkinson's disease are primarily caused by disturbed basal ganglia (dopamine) function, cerebellar dysfunction related to norepinephrine may contribute to some abnormalities of motor performance in this disorder.



Author Affiliations

From the Human Brain Laboratory, Clarke Institute of Psychiatry, Toronto (Drs Kish and Hornykiewicz and Ms Shannak); the University Hospital, Saskatoon, Saskatchewan (Dr Rajput); the Victoria Hospital, London (Dr Gilbert); and the Institute of Biochemical Pharmacology, University of Vienna (Dr Hornykiewicz).


Footnotes

Accepted for publication July 8, 1983.

Reprint requests to Human Brain Laboratory, Clarke Institute of Psychiatry, 250 College St, Toronto, Ontario, Canada M5T 1R8 (Dr Kish).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypertension Increases Cerebral 6-18F-Fluorodopa-Derived Radioactivity
Goldstein et al.
JNM 2009;50:1479-1482.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.